Aeolus Pharmaceuticals Inc (AOLS) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
26361 CROWN VALLEY PARKWAY, SUITE 150 MISSION VIEJO, CA 92691 |
| State of Incorp. | DE |
| Fiscal Year End | September 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2016 | 9/30/2015 | 9/30/2014 | 9/30/2013 | 9/30/2012 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 94 | 1,517 | 869 | 281 | |||
| Cash and cash equivalents | 94 | 1,517 | 869 | 281 | |||
| Receivables | 1,585 | 1,559 | 370 | 882 | |||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | 61 | ||
| Other undisclosed current assets | 66 | 472 | 696 | ||||
| Total current assets: | 1,745 | 3,548 | 1,935 | 1,224 | |||
| Noncurrent Assets | |||||||
| Long-term investments and receivables | 32 | 32 | 32 | 91 | |||
| Long-term investments | 32 | 32 | 32 | 91 | |||
| Deferred costs | 21 | 426 | 656 | ||||
| Other undisclosed noncurrent assets | (21) | (426) | (657) | (59) | |||
| Total noncurrent assets: | 32 | 32 | 31 | 32 | |||
| TOTAL ASSETS: | 1,777 | 3,580 | 1,966 | 1,256 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities, including: | 1,598 | 1,552 | 579 | 2,272 | |||
| Other undisclosed accounts payable and accrued liabilities | 1,598 | 1,552 | 579 | 2,272 | |||
| Debt | 727 | ||||||
| Deferred revenue and credits | 22 | 443 | 682 | ||||
| Other undisclosed current liabilities | 275 | ||||||
| Total current liabilities: | 2,622 | 1,995 | 1,261 | 2,272 | |||
| Noncurrent Liabilities | |||||||
| Other undisclosed noncurrent liabilities | 19,319 | ||||||
| Total noncurrent liabilities: | 19,319 | ||||||
| Total liabilities: | 2,622 | 1,995 | 1,261 | 21,591 | |||
| Equity | |||||||
| Equity, attributable to parent, including: | (845) | 1,585 | 705 | (20,335) | |||
| Preferred stock | 5 | 5 | 5 | 5 | |||
| Common stock | 1,359 | 1,359 | 1,346 | 627 | |||
| Additional paid in capital | 184,421 | 184,223 | 183,276 | 159,747 | |||
| Accumulated deficit | (186,630) | (184,002) | (183,922) | (180,714) | |||
| Warrants and rights outstanding | 275 | 19,319 | |||||
| Other undisclosed equity, attributable to parent | (275) | (19,319) | |||||
| Total equity: | (845) | 1,585 | 705 | (20,335) | |||
| TOTAL LIABILITIES AND EQUITY: | 1,777 | 3,580 | 1,966 | 1,256 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2016 | 9/30/2015 | 9/30/2014 | 9/30/2013 | 9/30/2012 | ||
|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 3,111 | 9,631 | 3,928 | 7,293 | ||
| Cost of revenue | (555) | |||||
| Gross profit: | 3,111 | 9,631 | 3,373 | 7,293 | ||
| Operating expenses | (6,142) | (9,941) | (6,071) | (9,664) | ||
| Other undisclosed operating income | 405 | 230 | ||||
| Operating loss: | (2,626) | (80) | (2,698) | (2,371) | ||
| Interest and debt expense | (2) | |||||
| Loss from continuing operations before income taxes: | (2,628) | (80) | (2,698) | (2,371) | ||
| Income tax expense | (2) | (2) | (2) | (2) | ||
| Loss from continuing operations: | (2,630) | (82) | (2,700) | (2,373) | ||
| Loss before gain (loss) on sale of properties: | (2,630) | (82) | (2,700) | (2,373) | ||
| Net loss: | (2,630) | (82) | (2,700) | (2,373) | ||
| Other undisclosed net income (loss) attributable to parent | 2 | 2 | (508) | 4,071 | ||
| Net income (loss) attributable to parent: | (2,628) | (80) | (3,208) | 1,698 | ||
| Other undisclosed net loss available to common stockholders, basic | ||||||
| Net income (loss) available to common stockholders, diluted: | (2,628) | (80) | (3,208) | 1,698 | ||
Comprehensive Income ($ in thousands)
| 9/30/2016 | 9/30/2015 | 9/30/2014 | 9/30/2013 | 9/30/2012 | ||
|---|---|---|---|---|---|---|
| Net loss: | (2,630) | (82) | (2,700) | (2,373) | ||
| Comprehensive loss, net of tax, attributable to parent: | (2,630) | (82) | (2,700) | (2,373) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.